Drugs / AVL-3288
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03281694 | May 2018 → Feb 2019 | — | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 1 | NCT02978599 | Nov 2016 → Oct 2018 | schizoaffective disorder, schizophrenia | New York State Psychiatric Institute | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVL-3288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03281694 ↗ |
| Known as | Anvylic-3288 | ChEMBL registry synonym — accepted as the source's own label CHEMBL429317 ↗ |
| Known as | CCMI | ChEMBL registry synonym — accepted as the source's own label CHEMBL429317 ↗ |
| Known as | UCI-4083 | ChEMBL registry synonym — accepted as the source's own label CHEMBL429317 ↗ |
| Known as | XY-4083 | ChEMBL registry synonym — accepted as the source's own label CHEMBL429317 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator” CHEMBL429317 ↗1“Positive Allosteric Modulator at the alpha7 Nicotinic Cholinergic Receptor” NCT02978599 ↗ |
| Modality | Small molecule | — CHEMBL429317 ↗ |
| Route | Oral | “two oral doses of AVL-3288” NCT02978599 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator” CHEMBL429317 ↗ |